IV obesity and atrial fibrillation or flutter, achieving a 92.3% success rate without any airway events, a study finds.
ROME, ITALY — Using the factor Xa inhibitor edoxaban (Savaysa/Lixiana, Daiichi Sankyo) to anticoagulate patients about to undergo electrical cardioversion for their atrial fibrillation (AF) seems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback